Combination 5-FU / Calcipotriene Cream for SCCIS/SCC
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The study will determine if calcipotriene and 5-fluorouracil (5-FU) creams when combined can
treat SCCIS and superficially invasive SCC (but not deeply invasive or high-risk cutaneous
SCC). 30 Patients will be divided into a 7 day treatment group (n=10), a 14 day treatment
group (n=10), and a placebo group (n=10, divided into 7 and 14 days evenly). Following
treatment with the topical chemotherapeutic medication, tumors would be completely excised
according to standard of care, and specimens would be sent to pathology to determine if there
was residual tumor/margin clearance. The potential benefit of this intervention would be the
establishment of a non-invasive treatment that leads to minimal to no scarring or
complications (akin to topical 5-FU alone) but would require a much shorter and more
tolerable treatment duration (1-2 weeks) compared to available alternatives.